Tillomed Laboratories Limited, the European arm of Emcure Pharmaceuticals Ltd., has entered into an Asset Purchase Agreement (APA) with UK-based Manx Healthcare Limited, along with its subsidiaries Manx Pharma Ltd and Manx Generics Ltd. Through this agreement, Tillomed will acquire Manx’s product portfolio, including relevant Dossiers, Marketing Authorisations, Intellectual Property, and associated inventory, valued at approximately £19.7 million.
This includes an upfront payment of £6.2 million, with the remaining balance paid as milestone payments over the next 18 months. This strategic acquisition marks a key step in Tillomed’s expansion, reinforcing its market position and enhancing its ability to meet the dynamic needs of the pharmaceutical market.
Ajit Srimal, CEO of Tillomed, commented, “The acquisition of Manx’s well-established portfolio of high-quality products strengthens our ability to deliver accessible healthcare solutions. This acquisition will help us diversify our product range and solidify our presence in the market, aligning with our ongoing commitment to providing quality medicines.”
Tillomed Laboratories Limited, a subsidiary of Emcure Pharmaceuticals Ltd., is a leading European pharmaceutical company headquartered in Luton, UK. Tillomed specializes in developing, licensing, and marketing high-quality generic medicines across multiple European markets. With over 100 products in its portfolio, Tillomed works to ensure cost-effective healthcare solutions are accessible to patients across Europe. As part of Emcure, Tillomed benefits from cutting-edge research, manufacturing, and distribution expertise.
Emcure Pharmaceuticals Ltd (EPL), headquartered in Pune, India, is a global leader in the development, manufacture, and marketing of a wide range of pharmaceutical products. With a strong focus on innovation and patient-centered care, Emcure has established itself as a major player in several therapeutic areas. Founded in 1981, Emcure is ranked as India’s 12th largest pharmaceutical company in terms of domestic sales (as of MAT June 2024) and operates in more than 70 countries, including Europe and Canada.
